Viewing nowCombinationOldip Tablet 5/20mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.

MFDS item code 201404994 · Approved 2014.10.28 · Insurance code 640902820
Treatment of essential hypertension not controlled with monotherapy
This medication is used for the treatment of patients with essential hypertension when blood pressure is not adequately controlled with either amlodipine or olmesartan medoxomil monotherapy. It effectively lowers blood pressure and helps reduce the risk of complications related to hypertension.
Take 1 tablet once daily with water, with or without food. It is recommended, if possible, to take this medicine at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine must not be administered to patients with severe hepatic impairment. (See section 2, Patients who must not be administered this medicine, under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
Safety and efficacy have not been established in pediatric patients under 18 years of age.
This medication may cause serious harm to the fetus and newborn when taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Individuals with allergies to this medication’s active ingredients or similar substances, pregnant or nursing women, patients with severe liver impairment or aortic stenosis, patients on dialysis, patients in shock, and certain diabetic patients should not take this medication. Patients with hypotension due to lack of fluids or salt and those at risk of rapid vascular dilation, patients with severe obstructive coronary artery disease, congestive heart failure patients, and patients with impaired kidney function should be particularly cautious when taking this medication and should be closely monitored. This medication can cause various side effects such as dizziness, headache, hypotension, edema, and dyspepsia, so any unusual symptoms should be reported to a healthcare professional immediately. Suddenly stopping beta-blockers may be dangerous, so when taking this medication, the dose of the beta-blocker should be gradually reduced. This medication may interact with other drugs, so patients taking other medications must inform their doctor or pharmacist. It is generally advised not to use this medication during pregnancy, particularly in the second and third trimesters, as it can have fatal effects on the fetus. Nursing women should consider stopping breastfeeding or discontinuing the medication, as it may be transmitted through breast milk. The safety and efficacy of this medication have not been established in individuals under 18 years of age. Elderly individuals may have decreased kidney and liver function, therefore they should start at a lower dose and have their dose adjusted with caution. Severe hypotension or heart problems may occur in cases of overdose, so the prescribed dosage must be strictly followed, and if any unusual symptoms arise, the patient should visit a hospital immediately. This medication should be stored out of reach of children, in a cool place protected from direct sunlight and moisture.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is recommended to keep it at room temperature between 1 degree and 30 degrees Celsius. Maintaining appropriate temperature and container conditions will safely preserve the efficacy of the medication.
White round film-coated tablets
28 tablets/box [(14 tablets/PTP x 2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.